最佳药物治疗对血运重建后10年死亡率的影响
该研究为SYNTAXES研究亚组分析,纳入1472例三支病变和/或左主干病变患者,评估5年时最佳药物治疗(OMT)状态与10年死亡率的关系。结果显示5年时接受OMT的患者10年死亡率显著低于≤2种药物者(13.1% vs 19.9%;调整HR 0.470;95%CI 0.292-0.757;P=0.002),但与3种药物者相似。
要点
- 5年时OMT与10年死亡率显著降低相关,优于≤2种药物。
- OMT与3种药物者的10年死亡率相似。
- CABG后使用抗血小板药和他汀者10年死亡率更低。
核心结论
- 在三支病变和/或左主干病变行PCI或CABG的患者中,5年时用药状态对10年死亡率有显著影响。
- 5年时接受指南推荐药物联合OMT的患者有生存获益。
研究设计与样本
- SYNTAXES研究亚组分析,评估原SYNTAX试验患者最长10年生存状态。
- OMT定义为至少1种抗血小板药、他汀、ACEI/ARB和β受体阻滞剂四类药物的组合。
- 按5年时OMT药物种类数和随机治疗分组后进行landmark分析。
- 共纳入1472例患者。
主要发现
- 5年时OMT患者10年死亡率13.1%,≤2种药物者19.9%(调整HR 0.470;95%CI 0.292-0.757;P=0.002)。
- 5年时OMT患者10年死亡率与3种药物者相似。
- CABG后5年时使用抗血小板药和他汀者10年死亡率低于未使用者。
临床怎么用
- 对三支病变和/或左主干病变血运重建后患者,应关注5年时OMT落实情况以改善长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of optimal medical therapy (OMT) on 5-year outcomes in patients with 3-vessel disease and/or left main disease after percutaneous coronary intervention or coronary artery bypass grafting (CABG) was demonstrated in the randomized SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) trial. OBJECTIVES: The objective of this analysis is to assess the impact of the status of OMT at 5 years on 10-year mortality after percutaneous coronary intervention or CABG. METHODS: This is a subanalysis of the SYNTAXES (Synergy Between PCI With Taxus and Cardiac Surgery Extended Survival) study, which evaluated for up to 10 years the vital status of patients who were originally enrolled in the SYNTAX trial. OMT was defined as the combination of 4 types of medications: at least 1 antiplatelet drug, statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and beta-blocker. After stratifying participants by the number of individual OMT agents at 5 years and randomized treatment, a landmark analysis was conducted to assess the association between treatment response and 10-year mortality. RESULTS: In 1,472 patients, patients on OMT at 5 years had a significantly lower mortality at 10 years compared with those on ≤2 types of medications (13.1% vs 19.9%; adjusted HR: 0.470; 95% CI: 0.292-0.757; P = 0.002) but had a mortality similar to those on 3 types of medications. Furthermore, patients undergoing CABG with the individual OMT agents, antiplatelet drug and statin, at 5 years had lower 10-year mortality than those without. CONCLUSIONS: In patients with 3-vessel and/or left main disease undergoing percutaneous coronary intervention or CABG, medication status at 5 years had a significant impact on 10-year mortality. Patients on OMT with guideline-recommended pharmacologic therapy at 5 years had a survival benefit. (Synergy Between PCI With Taxus and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; Taxus Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries [SYNTAX]; NCT00114972).
引用
- Kawashima H, Serruys PW, Ono M, et al. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. J Am Coll Cardiol. 2021. PMID: 34210411. doi:10.1016/j.jacc.2021.04.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。